Analyst Rating Update on Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) : The consensus on Regeneron Pharmaceuticals (NASDAQ:REGN) based on 19 analyst recommendation on the company stock is 2.53, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 6 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 10 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 2 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Regeneron Pharmaceuticals (NASDAQ:REGN) : The most positive equity analysts on Regeneron Pharmaceuticals (NASDAQ:REGN) expects the shares to touch $668, whereas, the least positive believes that the stock will trade at $325 in the short term. The company is covered by 18 Wall Street Brokerage Firms. The average price target for shares are $489.94 with an expected fluctuation of $82.74 from the mean.

For the current week, the company shares have a recommendation consensus of Buy.

Regeneron Pharmaceuticals (NASDAQ:REGN): stock turned positive on Tuesday. Though the stock opened at $334.47, the bulls momentum made the stock top out at $340.43 level for the day. The stock recorded a low of $332.97 and closed the trading day at $339.78, in the green by 2.64%. The total traded volume for the day was 806,041. The stock had closed at $331.05 in the previous days trading.

In an insider trading activity,The director of Regeneron Pharmaceuticals Inc, Ryan Arthur F sold 1,000 shares at $396.64 on May 24, 2016. The Insider selling transaction had a total value worth of $396,640. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Regeneron Pharmaceuticals, Inc. is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Companys marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.